AI Driven Drug Discovery Summit

𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗔𝗜 𝗗𝗿𝗶𝘃𝗲𝗻 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗦𝘂𝗺𝗺𝗶𝘁, 𝗕𝗼𝘀𝘁𝗼𝗻 2024 🙌 Our participation in the AI Driven Drug Discovery Summit 2024 in Boston was an incredible success! The three-day event brought together the brightest minds in pharma, biotech and academia, providing a unique platform to exchange ideas, showcase innovations and forge meaningful connections. At Medvolt, we had the privilege of engaging with industry leaders, researchers and entrepreneurs who share our passion for revolutionizing drug discovery. Our AI-accelerated platform sparked insightful discussions, with attendees showing great interest in how we fast-track drug discovery projects by up to 3x while reducing costs by 5x, as validated through real-world use cases. The summit also provided a valuable opportunity to build new partnerships and strengthen existing ones. Through dynamic panel discussions, one-on-one meetings and networking sessions, we explored potential collaborations that could drive transformative change in the industry. Sharing our vision with like-minded professionals was a truly rewarding experience. We’re especially thrilled about the feedback and ideas we received during our conversations. These exchanges have not only reinforced our commitment to innovation but also inspired new approaches for future projects. A heartfelt thank you to the organizers, speakers and attendees who made this summit an unforgettable experience. 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿, 𝘄𝗲’𝗿𝗲 𝘀𝗵𝗮𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆, 𝗼𝗻𝗲 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗶𝗱𝗲𝗮 𝗮𝘁 𝗮 𝘁𝗶𝗺𝗲𝗅 AI Driven Drug Discovery Summit || Madhura Vipra, PhD || Ritvik V. #aidd #aidrivendrugdiscoverysummit #drug #drugdiscovery #biotech #healthtech #healthcare #llm #genai #ml #ai

Could AI be a meaningful solution for end-to-end drug discovery? 🤔 I had the privilege of diving into this exciting topic at the AI Driven Drug Discovery Summit, alongside an incredible panel of experts. We discussed the transformative potential of AI across the drug discovery process—from target identification to clinical trial design—and the opportunities it presents to accelerate innovation and improve outcomes for patients. A big thank you to my fellow panelists for their invaluable insights and thought-provoking perspectives. Conversations like these remind me of the power of collaboration in shaping the future of our industry. I’m eager to see how AI continues to redefine what’s possible in drug discovery! 🚀 Petrina Kamya, Ph.D. from Insilico Medicine, Ari Allyn-Feuer from GSK, Chirag Sachar, PhD from Novartis, Charles W. O'Donnell from Omega Therapeutics, Niamh Middlemass

👏 Event Recap: Thank you to the organizers at Kiasco Research for planning #AIDD2024, featuring Petrina Kamya, Ph.D., Global Head of AI Platforms, Vice President of Insilico Medicine Canada. This year’s event highlights focused on: -Balancing AI's Promises and Challenges AI is transforming drug discovery, showing promise in #preclinical research, but clinical success is still a challenge. -The Importance of #DataQuality and Sharing for AI High-quality, diverse data is essential for effective AI. Datasharing ensures inclusivity and accuracy. -The Power of Collaboration in AI-Driven Drug Development Cross-functional collaboration is crucial for AI-driven drug development to tackle challenges and maximize AI's potential. -#QuantumComputing and AI in #DrugDiscovery Quantum computing and autonomous systems, combined with AI, are unlocking new possibilities in drug discovery. For video coverage, photos and more, please visit: https://lnkd.in/euBEF9-7 We hope to see you next year at #AIDD2025!

Honored to speak at the AI-Driven Drug Discovery Conference and unveil Victoria 2.0, a generative AI solution I built to predict genomic mutations and evolution in biological viruses. Victoria 2.0 is designed to forecast how viruses like influenza, HPV, Zika, and Ebola will evolve. By forecasting viral evolution with precision, we can take a proactive approach to engineering countermeasures—staying one step ahead of these viruses. This project has been a labor of passion and precision, and I’m proud to see it contribute to reshaping vaccine development and antiviral strategies. A heartfelt thank you to the conference organizers and attendees for the engaging discussions and for fostering a space where innovation can thrive. Together, we’re reshaping what’s possible in drug discovery and healthcare. AI Driven Drug Discovery Summit Niamh Middlemass #AI #GenerativeAI #HealthcareInnovation #DrugDiscovery #Vaccines

Three weeks ago, we gathered in Boston for the 3rd #AIDDD Summit with trailblazers and innovators to explore how AI is transforming drug discovery and development. Now, we're excited to share our highlights from this year's summit! 📽️🌟 Download the post-event report here to discover our key takeaways 👉https://hubs.ly/Q02ZZGJw0 📢 If you haven't heard, we'll be back in Boston on November 18-20, 2025 and would love to see you there! Make sure to register your interest: https://hubs.ly/Q02ZZFT50 #AIDDD #aidrivendrugdiscoverysummit #aidrivendrugdiscovery #aidrugdiscovery #drugdiscovery

QP recently attended the AI Driven Drug Discovery Summit in Boston, taking in some groundbreaking discussions on how AI is helping to reframe the future of drug discovery and healthcare innovation. Ideas and insights shared throughout the summit reinforced the incredible pace of progress that is ongoing in the field.    One critical question from the summit: are the targets good enough? AI’s potential role in biological validation offers a transformative approach to both druggable and previously undruggable spaces, emphasizing the importance of building well-controlled, high-quality datasets.     Equally fascinating is AI's potential in the clinical space, where early successes are highlighting the ability to accelerate projects to Phase 1 trials and promising applications for interpreting clinical data.    As companies continue to integrate #AI in their pipeline, it’s clear that progress hinges on collaboration and cross-functional teams—those capable not only of navigating data and computer science but also of integrating expertise from fields like biology and chemistry—emphasizing the critical need to dismantle silos within the industry to drive meaningful advancements.    👉 Thank you #AIDDD for convening such a diverse array of experts and topics, it was truly an informative and thought-provoking summit! Philipp Trepte #AIDrugDiscovery #AIDrivenDrugDiscovery 

Feeling extremely humbled and grateful to share that BioBox won the inaugural Innovation Incubator competition at the AI Driven Drug Discovery Summit! During this competition we were fortunate to share our vision and framework for knowledge management in drug discovery to an audience of scientists, executives, and investors in the pharmaceutical industry in an intimate environment. As an early stage startup in this space, getting exposure is critical to unlocking opportunities to prove your value. That is why I am so thankful to the judges and the organizers for this opportunity. Since this event, I am thrilled to share that we've opened new opportunities to collaborate with many cutting-edge biotechnology companies, including 4 of the top 20 pharma companies. Reflecting back on our humble beginnings as scientists and graduate students at the University of Toronto and The Hospital for Sick Children looking to build out a new way to organize biomedical knowledge. Gaining support from our thriving entrepreneurship ecosystem here in Toronto from organizations such as MaRS Discovery District, UTEST, University of Toronto. Finding investors like 2048 Ventures and Contrary capital who were willing to believe in us and our crazy idea. Through to our first customers like the incredible team at Flare Therapeutics. We are so thankful for your support. Lastly, none of this would have been possible without my incredible team Hamza Farooq, Julian Mazzitelli, and Lauren Phillips. I owe you the world. Proud of all we've accomplished. This is for you guys. Let's go build the future of knowledge management in biopharma research. 🚀

A breath of fresh air at the AI Driven Drug Discovery Summit speaking with some many organizations that are doing groundbreaking work with AI and ML to accelerate the delivery of new treatments. We are very proud at Vultr to enable this work that impacts lives so directly. Great to see Markandeya Korula, Aleks Shar, MBA, Jaeson Nicolopulos and Lora Kratchounova

🌟 This fab video of the #AI Driven Drug Discovery summit in Boston earlier this week gives an accurate impression of the event. 💡 Great ideas for the future role of AI in drug discovery and current activity in this fast evolving technology, 🤝 Opportunities for networking and meeting lots of very innovative and ambitious people looking to improve drug discovery, 🍷 Good hospitality which really helps the whole event come together, and 🗣️ Great speakers with real insight and passion for their work. 🎬 I also enjoyed spotting myself in the vid! Thanks Kisaco Research for a fascinating and fun event. HGF Limited #DrugDiscovery #Bioinformatics #AI #ArtificialIntelligence #Conference #Networking

🚀 Exciting Highlights from the AI Driven Drug Discovery Summit! 🚀 Our #VPE Team Lead, Douglas McCloskey, represented BioMed X Institute with inspiring insights at the AI Driven Drug Discovery Summit in Boston from November 12-14! 🌐✨ He shared the latest advancements from his #VPE Team, which, in partnership with Sanofi, is pioneering research on the Next Generation Virtual Patient Engine to accelerate the clinical translation of drug candidates. He also engaged with top industry leaders on the future of AI-driven drug discovery, fostering insightful discussions on its transformative potential. Douglas also joined QIAGEN’s pre-day Knowledge Graph Insight Session, diving into the powerful role of knowledge graphs in modern biopharma research. 📊🤖 Here’s a quick recap of the summit highlights: 👉 Virtual patients (sometimes referred to as DigitalTwins) have the potential to reduce #DrugDiscovery and #DrugDevelopment in the #Pharmaceutical industry time and cost while improving access to life changing treatments to underrepresented patient populations. 👉 High quality (curated) biomedical #KnowledgeGraphs (such as the QIAGEN BKB-HD) are critical enablers to build virtual patients using knowledge-driven or data-driven in silico science. 👉 #AI enabled agentic workflows can expedite manual tasks related to building knowledge graphs and can democratize access to virtual patient technologies. See results (link in the first comment) from our most recent #Hackathon (VPE) "Results for AI agents for life sciences". Thank you to everyone who connected with us at the summit! We’re thrilled to bring back valuable insights and continue driving innovation in clinical translation and drug development. 🙌💡 Douglas McCloskey | Kyle Nilson, PhD | Ted Johnson | Scott J Magin | SHU YAN | Venkatesh Moktali, PhD | Are you interested in how AI agents can revolutionize Pharma R&D by seamlessly communicating with PK/PD/QSP models and Biomedical Knowledge Graphs? 📊🤖 Don’t miss our upcoming webinar in collaboration with Code Ocean: AI Agents for Pharma R&D 📅 Date: November, 26, 2024 ⏰ Time: 6 pm Berlin / 12 pm EST / 9 am PT Register Now: AI Agents for Pharma R&D https://lnkd.in/eXZs5Gtr #BioMedX #AIDrugDiscovery #VirtualPatients #ClinicalTranslation #KnowledgeGraph #Biopharma #InnovationInBiotech #FutureOfMedicine #AIDDD